Clinical Trial News and Research

RSS

Fetal heart rate monitor may improve infant's health

Despite the numerous medical advances that happen every day, the infant mortality rate in the United States is still higher than most European countries. While experts believe this is closely linked to the growing rate of pre-term births, researchers are committed to finding ways to make labor and delivery safer. Northwestern Medicine- researchers are examining a new device that may support improved newborn health at delivery through closer monitoring of infant oxygen use during labor.

22 Dec 2011

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.

22 Dec 2011

Scientists discover N-cadherin as promising therapeutic target for pancreatic cancer

Often, and without much warning, pancreatic cancer cells slip through the endothelial cells, head into the blood and out to other parts of the body to metastasize, making it one of the deadliest and hardest to treat cancers today.

22 Dec 2011

Researchers evaluate Clade C HIV envelope protein in Phase I trial

In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University London, Imperial College, Hull York Medical School (HYMS; University of York) and the Medical Research Council Clinical Trial Unit) and from the Infectious Disease Research Institute (IDRI) have come together to evaluate whether the vaccine is safe for use in human volunteers.

22 Dec 2011

FDA approves Merck's Isentress to treat HIV-1 infection in children, adolescents

Isentress (raltegravir) was approved today by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18.

22 Dec 2011

Reva Medical commences its first clincial trial

Reva Medical, a medical device company, has today commenced the very first clinical trial of its ReZolve™ bioresorbable coronary stent. A patient in Brazil was implanted with the device overnight, which flags an exciting chapter for Reva Medical.

21 Dec 2011

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management Inc. announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome.

21 Dec 2011

Chlorthalidone may reduce risk of death in patients with systolic hypertension

Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.

21 Dec 2011

Antihypertensive drug therapy associated with longer life expectancy

More than 68 percent of Americans 65 and older - 80 percent age 75 and over - have hypertension (high blood pressure), according to a 2010 report by the Centers for Disease Control. Left untreated, this chronic condition can lead to stroke, heart attack, heart failure or premature death. Researchers at UMDNJ-Robert Wood Johnson Medical School have shown in a follow-up to the landmark clinical trial, Systolic Hypertension in the Elderly Program (SHEP), that the use of antihypertensive drug therapy is associated with longer life expectancy.

21 Dec 2011

CLND may help reduce papillary thyroid cancer recurrence rates

Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women. A new study indicates that routinely removing lymph nodes in the neck in these cancer patients may help prevent the disease from coming back.

21 Dec 2011

Vacc-4x nasal vaccine can effectively treat HIV

Thirty years after AIDS was first described, there is still no effective vaccine against the HIV virus. Worldwide, roughly 33 million people are HIV-positive. Researchers are working to find out whether a HIV vaccine developed by a Norwegian biotech company can be administered nasally.

21 Dec 2011

Mammography appears to detect women with low-risk breast cancer

As a woman ages, her chances of being diagnosed with a lower-risk breast tumor increase, according to a novel study led by UCSF which found that for women over 50, a substantial number of cancers detected by mammograms have good prognoses.

20 Dec 2011

Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS

Genzyme, a Sanofi company, today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a, an approved injectable therapy, in people with relapsing forms of multiple sclerosis.

20 Dec 2011

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

19 Dec 2011

Exactech commences clinical trial to evaluate new cartilage repair technology

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials announced today it has initiated a prospective, randomized, multi-center, clinical trial to evaluate the safety and effectiveness of a new cartilage repair technology.

19 Dec 2011

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

The ALS Therapy Development Institute today announced a research agreement with Biogen Idec and UCB Pharma SA to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or Motor Neuron Disease.

19 Dec 2011

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.

19 Dec 2011

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of Z944, a novel oral T-type calcium channel blocker with demonstrated preclinical potential for the treatment of acute and inflammatory pain.

19 Dec 2011

Soybean compounds can increase effectiveness of radiation treatment for lung cancer

A Wayne State University researcher has shown that compounds found in soybeans can make radiation treatment of lung cancer tumors more effective while helping to preserve normal tissue.

19 Dec 2011

Patheon fourth quarter revenues increase to $181.6 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.

19 Dec 2011

Clinical Trial News and Research

Fetal heart rate monitor may improve infant's health

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

Scientists discover N-cadherin as promising therapeutic target for pancreatic cancer

Researchers evaluate Clade C HIV envelope protein in Phase I trial

FDA approves Merck's Isentress to treat HIV-1 infection in children, adolescents

Reva Medical commences its first clincial trial

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Chlorthalidone may reduce risk of death in patients with systolic hypertension

Antihypertensive drug therapy associated with longer life expectancy

CLND may help reduce papillary thyroid cancer recurrence rates

Vacc-4x nasal vaccine can effectively treat HIV

Mammography appears to detect women with low-risk breast cancer

Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Exactech commences clinical trial to evaluate new cartilage repair technology

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

Soybean compounds can increase effectiveness of radiation treatment for lung cancer

Patheon fourth quarter revenues increase to $181.6 million

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer